sulpiride 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
sulpiride derivatives and analogues 2537 15676-16-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sulpiride
  • sulpirid
  • sulpitil
  • sulpyrid
  • sursumid
A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)
  • Molecular weight: 341.43
  • Formula: C15H23N3O4S
  • CLOGP: 1.15
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 101.73
  • ALOGS: -2.80
  • ROTB: 6

Drug dosage:

DoseUnitRoute
0.80 g O
0.80 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 2.28 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 70 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 133.89 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 27 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.94 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 6.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1972 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Torsade de pointes 111.06 24.02 38 3630 13313 63472041
Electrocardiogram QT prolonged 109.71 24.02 58 3610 59472 63425882
Parkinsonism 76.34 24.02 27 3641 10412 63474942
Ventricular fibrillation 65.68 24.02 25 3643 11842 63473512
Cerebellar syndrome 62.85 24.02 18 3650 3521 63481833
Hypokalaemia 62.30 24.02 50 3618 103754 63381600
Serotonin syndrome 61.57 24.02 31 3637 28651 63456703
Suicide attempt 60.93 24.02 40 3628 60878 63424476
Fall 57.40 24.02 90 3578 392244 63093110
Hypomagnesaemia 55.71 24.02 29 3639 28708 63456646
Rhabdomyolysis 46.72 24.02 30 3638 43921 63441433
Extrapyramidal disorder 46.03 24.02 20 3648 13264 63472090
Fracture 44.48 24.02 22 3646 19562 63465792
Drug interaction 44.21 24.02 60 3608 229071 63256283
Psychomotor retardation 40.06 24.02 13 3655 3857 63481497
Altered state of consciousness 39.23 24.02 22 3646 25208 63460146
Tension 38.37 24.02 12 3656 3163 63482191
Hyponatraemia 35.91 24.02 38 3630 111862 63373492
Product monitoring error 34.22 24.02 12 3656 4504 63480850
Cardio-respiratory arrest 34.06 24.02 28 3640 59931 63425423
Long QT syndrome 33.88 24.02 11 3657 3268 63482086
Metabolic syndrome 32.38 24.02 9 3659 1579 63483775
Infectious mononucleosis 30.60 24.02 9 3659 1930 63483424
Hyperthermia 29.17 24.02 13 3655 9143 63476211
Somnolence 28.82 24.02 43 3625 178642 63306712
Persecutory delusion 27.37 24.02 9 3659 2781 63482573
Social anxiety disorder 26.94 24.02 6 3662 425 63484929
Drug abuse 25.72 24.02 26 3642 72492 63412862
Blood lactic acid increased 25.63 24.02 11 3657 7075 63478279
Pain 25.19 24.02 6 3662 740622 62744732
Dystonia 24.09 24.02 13 3655 13806 63471548
Enuresis 24.04 24.02 8 3660 2565 63482789

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Extrapyramidal disorder 58.91 27.79 24 2114 12856 34941937
Schizophrenia 53.23 27.79 20 2118 8646 34946147
Neuroleptic malignant syndrome 42.18 27.79 21 2117 17913 34936880
Suicide attempt 40.97 27.79 27 2111 39089 34915704
Mean cell haemoglobin concentration decreased 38.94 27.79 10 2128 1227 34953566
Eosinophil count decreased 37.52 27.79 10 2128 1418 34953375
Parkinsonism 36.63 27.79 15 2123 8123 34946670
Reduced facial expression 35.23 27.79 9 2129 1082 34953711
Pneumonia aspiration 32.36 27.79 24 2114 41879 34912914
Dissociative disorder 31.52 27.79 7 2131 462 34954331
Cognitive disorder 28.08 27.79 19 2119 28674 34926119

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QT prolonged 118.46 20.27 77 5807 90309 79648195
Parkinsonism 104.34 20.27 41 5843 16543 79721961
Extrapyramidal disorder 91.95 20.27 41 5843 22638 79715866
Torsade de pointes 91.61 20.27 39 5845 19273 79719231
Suicide attempt 74.31 20.27 56 5828 82876 79655628
Fall 59.92 20.27 119 5765 487510 79250994
Cerebellar syndrome 58.46 20.27 20 5864 5460 79733044
Psychomotor retardation 56.10 20.27 20 5864 6164 79732340
Neuroleptic malignant syndrome 55.56 20.27 31 5853 27528 79710976
Serotonin syndrome 50.82 20.27 35 5849 44992 79693512
Hypokalaemia 47.87 20.27 56 5828 143984 79594520
Rhabdomyolysis 46.32 20.27 47 5837 103084 79635420
Cognitive disorder 45.14 20.27 39 5845 69887 79668617
Tension 42.83 20.27 15 5869 4389 79734115
Hypomagnesaemia 42.70 20.27 32 5852 46879 79691625
Product prescribing error 41.75 20.27 31 5853 44782 79693722
Altered state of consciousness 40.12 20.27 30 5854 43792 79694712
Schizophrenia 38.48 20.27 20 5864 15420 79723084
Fracture 37.19 20.27 22 5862 21779 79716725
Ventricular fibrillation 36.45 20.27 25 5859 31901 79706603
Depressed mood 33.24 20.27 28 5856 48452 79690052
Hepatic function abnormal 30.43 20.27 32 5852 73075 79665429
Hyperthermia 27.66 20.27 17 5867 18020 79720484
Somnolence 27.64 20.27 57 5827 238924 79499580
Pneumonia aspiration 27.31 20.27 29 5855 66938 79671566
Eosinophil count decreased 27.12 20.27 10 5874 3386 79735118
Dissociative disorder 26.31 20.27 7 5877 814 79737690
Drug interaction 25.72 20.27 78 5806 415105 79323399
Intentional overdose 25.34 20.27 35 5849 105925 79632579
Atopic keratoconjunctivitis 25.06 20.27 4 5880 34 79738470
Hyponatraemia 24.91 20.27 46 5838 177802 79560702
Long QT syndrome 24.87 20.27 11 5873 5944 79732560
Mean cell haemoglobin concentration decreased 24.22 20.27 10 5874 4569 79733935
Social anxiety disorder 23.80 20.27 6 5878 565 79737939
Product monitoring error 23.53 20.27 12 5872 8894 79729610
Anxiety 21.69 20.27 53 5831 248459 79490045
Neutrophil count decreased 20.93 20.27 30 5854 93929 79644575
Disturbance in attention 20.71 20.27 22 5862 50779 79687725
Mixed anxiety and depressive disorder 20.53 20.27 5 5879 408 79738096
Sopor 20.46 20.27 18 5866 32992 79705512
Dystonia 20.36 20.27 15 5869 21384 79717120

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AL01 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Benzamides
MeSH PA D000928 Antidepressive Agents
MeSH PA D018687 Antidepressive Agents, Second-Generation
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:35476 neuroleptics
CHEBI has role CHEBI:48561 dopaminergic antagonists
CHEBI has role CHEBI:50919 antiemetico

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Schizophrenia indication 58214004 DOID:5419




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.47 acidic
pKa2 12.66 acidic
pKa3 8.85 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.12 CHEMBL IUPHAR
Alpha-2A adrenergic receptor GPCR Ki 6.12 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 8.10 CHEMBL
D(4) dopamine receptor GPCR Ki 5.68 CHEMBL
Carbonic anhydrase 2 Enzyme IC50 7.40 WOMBAT-PK
Carbonic anhydrase 1 Enzyme Ki 5.92 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 7.51 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 8.41 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 6.76 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 7.74 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 8.44 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 4.97 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 9.10 CHEMBL
Carbonic anhydrase Enzyme Ki 6.75 CHEMBL
D(2) dopamine receptor GPCR Kd 8.82 CHEMBL
D(2) dopamine receptor GPCR IC50 6.70 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 7.14 CHEMBL
Carbonic anhydrase Enzyme Ki 6.91 CHEMBL
Carbonic anhydrase Enzyme Ki 7.40 CHEMBL
Carbonic anhydrase Enzyme Ki 6.95 CHEMBL
Alpha carbonic anhydrase Enzyme Ki 6.37 CHEMBL
Carbonic anhydrase Enzyme Ki 6.38 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 6.09 CHEMBL
Astrosclerin-3 Enzyme Ki 6.42 CHEMBL
Beta-carbonic anhydrase 1 Enzyme Ki 5.64 CHEMBL
Delta carbonic anhydrase Unclassified Ki 6.59 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 6.58 CHEMBL
Dopamine receptor GPCR Ki 5.80 CHEMBL
Carbonic anhydrase Enzyme Ki 7.53 CHEMBL
Carbonic anhydrase, alpha family Unclassified Ki 6.06 CHEMBL
Carbonate dehydratase Enzyme Ki 7.17 CHEMBL

External reference:

IDSource
N0000166882 NUI
D01226 KEGG_DRUG
C0038803 UMLSCUI
CHEBI:32168 CHEBI
CHEMBL26 ChEMBL_ID
DB00391 DRUGBANK_ID
D013469 MESH_DESCRIPTOR_UI
5355 PUBCHEM_CID
5501 IUPHAR_LIGAND_ID
2359 INN_ID
7MNE9M8287 UNII
10239 RXNORM
003764 NDDF
321506004 SNOMEDCT_US
395891007 SNOMEDCT_US

Pharmaceutical products:

None